Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A rare brain disorder finally has a treatment. The FDA approved zilganersen (Zanvastro) as the first-ever therapy for Alexander disease, a progressive neurological disorder affecting fewer than 1 in a million people. The drug targets the root cause — a toxic protein buildup in the brain — and is approved for patients from infancy through adulthood.
A landmark moment for a tiny patient community. The FDA has approved zilganersen (Zanvastro), marking the first-ever approved treatment for Alexander disease — a rare, progressive neurological disorder caused by mutations in the GFAP gene. Until now, patients had only supportive care as the disease worsened. Zilganersen is an antisense oligonucleotide that reduces abnormal GFAP protein production before it can accumulate in brain cells and cause damage to neurons and myelin.
The approval covers patients from infancy through adulthood. In a randomized controlled trial of 49 patients aged 2 and older, treated patients aged 5 and older showed significantly better walking speed at 61 weeks versus untreated controls, while children aged 2–4 showed improved gross motor skills as the control group declined. For infants under 2, pharmacokinetic modeling and safety data from four treated infants supported extending the indication.
Key Takeaways:
Why it matters: Alexander disease affects fewer than 1 in a million people worldwide and has no cure. This approval is the first therapy to address the disease's underlying cause, offering meaningful hope to patients and families who previously had no disease-modifying options.
